CD8A and neoplasm: In human and mouse lung cancer, PLX3397, a CSF1R inhibitor, reversed the long-term interaction between CD8 T cells and TAMs, thereby depleting TAM and inhibiting the migration and infiltration of T cells at the tumor site.